Inclusion Criteria:

          1. Able to give written informed consent and to comply with the protocol

          2. Metastatic oestrogen receptor positive and/or progesterone receptor positive breast
             adenocarcinoma, histologically proven by biopsy of the primary tumour and/or
             metastasis

          3. Female of age 18 years or above

          4. Patients who are indicated to received first line chemotherapy with weekly paclitaxel

          5. Evidence of measurable disease as defined by Response Evaluation Criteria version 1.1

        6 Laboratory criteria: haematology and biochemistry results within the limits normally
        expected for the patient population.

        Exclusion Criteria:

          1. Prior chemotherapy for metastatic breast adenocarcinoma

          2. Disease-free interval of less than twelve months from the last dose of adjuvant
             chemotherapy

          3. Inflammatory carcinoma

          4. Candidate for treatment with trastuzumab (or other Her2/neu targeted agents)

          5. Systemic chemotherapy, radiation therapy or any other investigational agent within 4
             weeks, endocrine therapy within 1 week prior to first dose of study treatment or
             CDK4/6 inhibitors within 5 times half-life (acc.to SPC) prior to first dose of study
             treatment and until completion of study treatment

          6. Symptomatic known cerebral and/or leptomeningeal metastases

          7. Serious intercurrent infection

          8. Evidence of severe or uncontrolled cardiac disease (NYHA III-IV) within 6 months prior
             to first dose of study treatment

          9. Active acute or chronic infection

         10. Active autoimmune disease requiring immunosuppressive therapy

         11. Previous malignancies within the last three years other than breast carcinoma

         12. Patients with prior organ or stem cell transplantation

         13. Any condition requiring continuous systemic treatment with either corticosteroids or
             other immunosuppressive medications within 4 weeks prior to first dose of study
             treatment.